{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T20:31:24Z","timestamp":1775334684817,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Regular and long-term injections of botulinum toxin (BoNT) are considered the first line therapy for essential blepharospasm (BEB), but no data exists on the long-term effect of this therapy on depressive symptoms and quality of life. This study aims to prospectively evaluate the long-term effects of BoNT therapy on depressive symptoms as well as on daily activities, emotional well-being and quality of life using validated questionnaires (BEB-scale, Beck`s Depression Inventory (BDI)). 86 patients diagnosed with BEB were followed up for a median of 4 years. Clinical symptoms improved significantly after BoNT-injections. Everyday activities and subjective assessment of the overall situation improved gradually under long-term BoNT therapy. Significant correlations (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001; r-values between 0.498 and 0.706) were found between the BDI and items of the BEB-scale. No significant antidepressive effect of long-term BoNT therapy was found with a low median BDI total score (5\/max. 63), but up to 31.3% of BEB patients had a BDI score\u2009\u2265\u200911, indicating clinically relevant depressive symptoms. Of these, 65.4% had no known history of depression. Although, several studies reported an antidepressant effect of botulinum toxin injections in patients with major depression, this effect does not seem to be present in patients with BEB despite clinical improvement of symptoms. A high prevalence of previously undetected depressive symptoms was found in BEB patients. As this may influence BoNT therapy success, identifying potential depressive symptoms at the time of BEB diagnosis and initiating appropriate treatment seems important.<\/jats:p>","DOI":"10.1007\/s13760-024-02658-y","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:41:23Z","timestamp":1730436083000},"page":"157-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-term therapy with botulinum toxin"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-114X","authenticated-orcid":false,"given":"Bettina","family":"Wabbels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Liebertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2658_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s004150070094","volume":"247","author":"Group ESoDiEC","year":"2000","unstructured":"Group ESoDiEC (2000) A prevalence study of primary dystonia in eight European coun-tries. J Neurol 247:787\u2013792","journal-title":"J Neurol"},{"key":"2658_CR2","doi-asserted-by":"publisher","unstructured":"Duarte GS, Rodrigus FB, Marques RE et al (2020) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev CD004900. https:\/\/doi.org\/10.1002\/14651858.CD004900.pub3","DOI":"10.1002\/14651858.CD004900.pub3"},{"key":"2658_CR3","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1001\/jama.1982.03330230060037","volume":"248","author":"J Jankovic","year":"1982","unstructured":"Jankovic J, Havins WE, Wilkins RB (1982) Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA 248:3160\u20133164","journal-title":"JAMA"},{"key":"2658_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/mds.1275","volume":"17","author":"G Defazio","year":"2001","unstructured":"Defazio G, Livrea P (2001) Epidemiology of primary blepharospasm. Mov Disord 17:7\u201312","journal-title":"Mov Disord"},{"key":"2658_CR5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004150070094","volume":"247","author":"ESDE","year":"2000","unstructured":"ESDE (2000) Epidemiological study of dystonia in europe. J Neurol 247:787\u2013792","journal-title":"J Neurol"},{"key":"2658_CR6","volume-title":"Botulinumtoxin-Therapie Im Kopf-Hals-Bereich","author":"P Roggenk\u00e4mper","year":"2004","unstructured":"Roggenk\u00e4mper P, Laskawi R (2004) Botulinumtoxin-Therapie Im Kopf-Hals-Bereich. Urban&Vogel, M\u00fcnchen"},{"key":"2658_CR7","unstructured":"Ip CW, Dystonie (2023) November, S1-Leitlinie. Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/dgn.org\/wp-content\/uploads\/2021\/04\/030039_LL_Dystonie_2021.pdf"},{"key":"2658_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenk\u00e4mper","year":"2006","unstructured":"Roggenk\u00e4mper P, Jost WH, Bihari K et al (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neur Transm 113:303\u2013312","journal-title":"J Neur Transm"},{"key":"2658_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00702-014-1278-z","volume":"122","author":"K Kollewe","year":"2015","unstructured":"Kollewe K, Mohammadi B, K\u00f6hler S et al (2015) Blepharospasm: long-term treatment with either Botox\u00ae, Xeomin\u00ae or Dysport\u00ae. J Neur Trans 122:427\u2013431","journal-title":"J Neur Trans"},{"key":"2658_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/NDT.S181820","volume":"15","author":"H Dong","year":"2019","unstructured":"Dong H, Fan S, Luo Y, Peng B (2019) Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm. Neuropsychiatr Dis Treat 15:33\u201336","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2658_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jns.2004.01.010","volume":"219","author":"EK Tan","year":"2004","unstructured":"Tan EK, Fook-Chong S, Lum SY, Lim E (2004) Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). J Neurol Sci 219:151\u2013155","journal-title":"J Neurol Sci"},{"key":"2658_CR12","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00415-002-0733-1","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller J, Kemmler G, Wissel J et al (2002) The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249:842\u2013846","journal-title":"J Neurol"},{"key":"2658_CR13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/mds.21049","volume":"21","author":"M Rinnerthaler","year":"2006","unstructured":"Rinnerthaler M, Mueller J, Weichbold V et al (2006) Social stigmatization in patients with cranial and cervical dystonia. Mov Disord 21:1636\u20131640","journal-title":"Mov Disord"},{"key":"2658_CR14","first-page":"645","volume":"32","author":"E Finzi","year":"2006","unstructured":"Finzi E, Wasserman E (2006) Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 32:645\u2013650","journal-title":"Dermatol Surg"},{"key":"2658_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.11.006","volume":"52","author":"E Finzi","year":"2014","unstructured":"Finzi E, Rosenthal NE (2014) Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo-controlled trial. J Psych Res 52:1\u20136","journal-title":"J Psych Res"},{"key":"2658_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.13m08845","volume":"75","author":"M Magid","year":"2014","unstructured":"Magid M, Reichenberg JS, Poth PE et al (2014) Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psych 75:837\u2013844","journal-title":"J Clin Psych"},{"key":"2658_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","volume":"46","author":"MA Wollmer","year":"2012","unstructured":"Wollmer MA, de Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatric Res 46:574\u2013581","journal-title":"J Psychiatric Res"},{"key":"2658_CR18","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fpsyt.2014.00036","volume":"5","author":"MA Wollmer","year":"2014","unstructured":"Wollmer MA, Kalak N, Jung S et al (2014) Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Front Psychiatry 5:36","journal-title":"Front Psychiatry"},{"key":"2658_CR19","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2147\/NDT.S141066","volume":"13","author":"JR Bedarf","year":"2017","unstructured":"Bedarf JR, Kebir S, Michelis JP et al (2017) Depression in blepharospasm: a question of facial feedback? Neuropsychiatr Dis Treat 13:1861\u20131865","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2658_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00702-021-02343-x","volume":"128","author":"B Wabbels","year":"2021","unstructured":"Wabbels B, Yaqubi A (2021) Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters. J Neur Trans 128:793\u2013802","journal-title":"J Neur Trans"},{"key":"2658_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J (1987) Botulinum a toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 37:616\u2013623","journal-title":"Neurology"},{"key":"2658_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00702-010-0546-9","volume":"118","author":"B Wabbels","year":"2011","unstructured":"Wabbels B, Jost WH, Roggenk\u00e4mper P (2011) Difficulties with differentiating botulinum toxin treatment effects in essential blepharospasm. J Neur Trans 118:925\u2013943","journal-title":"J Neur Trans"},{"key":"2658_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.22368","volume":"24","author":"J Jankovic","year":"2009","unstructured":"Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Dis 24:407\u2013413","journal-title":"Mov Dis"},{"key":"2658_CR24","first-page":"77","volume":"113","author":"S Goertelmeyer","year":"2002","unstructured":"Goertelmeyer S, Brinkmann G, Comes A, Delcker A (2002) The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol 113:77\u201378","journal-title":"Clin Neurophysiol"},{"key":"2658_CR25","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1136\/jnnp.2005.065656","volume":"76","author":"E Tan","year":"2005","unstructured":"Tan E, Fook-Chong S, Lum S, Thumboo J (2005) Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. J Neurol Neurosurg Psychiatry 76:1707\u20131710","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2658_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J (1961) An inventory for Measuring Depression. Arch Gen Psychiatry 4:561\u2013571","journal-title":"Arch Gen Psychiatry"},{"key":"2658_CR27","doi-asserted-by":"crossref","unstructured":"Beck A, Steer R (1987) Manual for the Beck Depression Inventory. The Psychological Corporation","DOI":"10.1007\/978-3-642-70486-4_13"},{"key":"2658_CR28","volume-title":"Beck-depressions-Inventar (BDI): Bearbeitung Der Deutschen Ausgabe","author":"M Hautzinger","year":"1994","unstructured":"Hautzinger M, Bailer M, Worall H, Keller F (1994) Beck-depressions-Inventar (BDI): Bearbeitung Der Deutschen Ausgabe. Testhandbuch, Hans Huber, Bern"},{"key":"2658_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.psychres.2004.03.014","volume":"135","author":"T Hiroe","year":"2005","unstructured":"Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y et al (2005) Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psych Res 135:229\u2013235","journal-title":"Psych Res"},{"key":"2658_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00115-013-3961-y","volume":"85","author":"F Jacobi","year":"2014","unstructured":"Jacobi F, H\u00f6fler M, Strehle J et al (2014) Psychische St\u00f6rungen in Der Allgemeinbev\u00f6lkerung Studie Zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). Nervenarzt 85:77\u201387","journal-title":"Nervenarzt"},{"key":"2658_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/toxins14020120","volume":"14","author":"B Wabbels","year":"2022","unstructured":"Wabbels B, Fimmers R, Roggenk\u00e4mper P (2022) Ultra-long-term Therapy of Benign essential blepharospasm with Botulinumtoxin A-30 years of experience in a Tertiary Care Center. Toxins 14:120. https:\/\/doi.org\/10.3390\/toxins14020120","journal-title":"Toxins"},{"key":"2658_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00702-013-0998-9","volume":"120","author":"DD Truong","year":"2013","unstructured":"Truong DD, Gollomp SM, Jankovic J et al (2013) Sustained efficacy and safety of repeated incobotulinumtoxin A (Xeomin(\u00ae)) injections in blepharospasm. J Neur Trans 120:1345\u20131353","journal-title":"J Neur Trans"},{"key":"2658_CR33","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s12325-020-01427-6","volume":"37","author":"DD Mitsikostas","year":"2020","unstructured":"Mitsikostas DD, Dekundy A, Sternberg K, Althaus M, Pagan F (2020) Incobotulinumtoxin A for the treatment of bleharospasm in Toxin-Na\u00efve subjects: a Multi-center, Double-Blind, randomized, placebo-controlled trial. Adv Ther 37:4249\u20134265","journal-title":"Adv Ther"},{"key":"2658_CR34","doi-asserted-by":"publisher","first-page":"e0283111","DOI":"10.1371\/journal.pone.0283111","volume":"18","author":"P Hirunwiwatkul","year":"2023","unstructured":"Hirunwiwatkul P, Supawatjariyakul W, Jariyakosol S et al (2023) Health-related quality of life of daily-life-affected benign essential blepharospasm: multi-center observational study. PLoS ONE 18:e0283111","journal-title":"PLoS ONE"},{"key":"2658_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/13548506.2018.1549740","volume":"24","author":"M Tang","year":"2019","unstructured":"Tang M, Li W, Ji F et al (2019) Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm. Psychol Health Med 24:513\u2013518","journal-title":"Psychol Health Med"},{"key":"2658_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clineuro.2018.06.040","volume":"172","author":"D Weiss","year":"2018","unstructured":"Weiss D, Hieber L, Sturm J et al (2018) T.Health-related quality of life outcomes from botulinumtoxin treatment in blepharospasm. Clin Neurol Neurosurg 172:130\u2013133","journal-title":"Clin Neurol Neurosurg"},{"key":"2658_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.parkreldis.2007.03.006","volume":"13","author":"S Ochudlo","year":"2007","unstructured":"Ochudlo S, Bryniarski P, Opala G (2007) Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord 13:505\u2013508","journal-title":"Parkinsonism Relat Disord"},{"key":"2658_CR38","first-page":"12","volume":"7","author":"T Kako","year":"2021","unstructured":"Kako T, Nokura K, Kaneko H, Izawa H (2021) Subjective assessment of effectiveness, quality of life, and psychological status of patients receiving botulinum toxin therapy for hemifacial spasm, blepharospasm, or cervical dystonia. Fujita Med J 7:12\u201317","journal-title":"Fujita Med J"},{"key":"2658_CR39","first-page":"110","volume":"40","author":"S Lawes-Wickwar","year":"2021","unstructured":"Lawes-Wickwar S, McBain H, Hirani SP et al (2021) Which factors impact on quality of life for adults with blepharospasm and hemifacial. spasm?Orbit 40:110\u2013119","journal-title":"spasm?Orbit"},{"key":"2658_CR40","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13760-014-0285-z","volume":"114","author":"M Streitov\u00e1H, Bare\u0161","year":"2014","unstructured":"Streitov\u00e1H, Bare\u0161 M (2014) Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg 114:285\u2013291","journal-title":"Acta Neurol Belg"},{"key":"2658_CR41","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s11136-011-9890-y","volume":"20","author":"S Setthawatcharawanich","year":"2011","unstructured":"Setthawatcharawanich S, Sathirapanya P, Limapichat K, Phabphal K (2011) Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin. Qual Life Res 20:1519\u20131523","journal-title":"Qual Life Res"},{"key":"2658_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/01676830490506041","volume":"23","author":"K MacAndie","year":"2004","unstructured":"MacAndie K, Kemp E (2004) Impact on quality of life of botulinum toxin treatments for essential blepharospasm. Orbit 23:207\u2013210","journal-title":"Orbit"},{"key":"2658_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1034\/j.1600-0404.2001.00109.x","volume":"103","author":"O Tucha","year":"2001","unstructured":"Tucha O, Naumann M, Berg D, Alders GL, Lange KW (2001) Quality of life in patients with blepharospasm. Acta Neurol Scand 103:49\u201352","journal-title":"Acta Neurol Scand"},{"key":"2658_CR44","doi-asserted-by":"crossref","unstructured":"Junker J, Berman BD, Hall J et al (2021) Quality of life in isolated dystonia: non-motor manifestations matter. J Neurol Neurosurg Psychiatry jnnp-2020-325193.","DOI":"10.1136\/jnnp-2020-325193"},{"key":"2658_CR45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/mds.10114","volume":"17","author":"DJ Burn","year":"2002","unstructured":"Burn DJ (2002) Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson\u2019s disease. Mov Disord 17:445\u2013454","journal-title":"Mov Disord"},{"key":"2658_CR46","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1176\/ajp.149.4.443","volume":"149","author":"JL Cummings","year":"1992","unstructured":"Cummings JL (1992) Depression and Parkinson\u2019s disease: a review. Am J Pyschiatry 149:443\u2013454","journal-title":"Am J Pyschiatry"},{"key":"2658_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5498\/wjp.v10.i6.139","volume":"10","author":"A Brunes","year":"2020","unstructured":"Brunes A, Heir T (2020) Visual impairment and depression: age-specific prevalence, associations with vision loss, and relation to life satisfaction. World J Psychiatry 10:139\u2013149","journal-title":"World J Psychiatry"},{"key":"2658_CR48","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5334\/tohm.466","volume":"9","author":"N Novaretti","year":"2019","unstructured":"Novaretti N, Cunha AL, Bezerra TC et al (2019) The prevalence and correlation of non-motor symptoms in adult patients with idiopathic focal or segmental Dystonia. Tremor Other Hyperkinet Mov (N Y) 9:596","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"2658_CR49","doi-asserted-by":"publisher","first-page":"938632","DOI":"10.3389\/fneur.2022.938632","volume":"13","author":"M Yi","year":"2022","unstructured":"Yi M, Li J, Liu G et al (2022) Mental health and quality of life in patients with craniofacial movement disorders: a cross-sectional study. Front Neurol 13:938632","journal-title":"Front Neurol"},{"key":"2658_CR50","unstructured":"Wittchen HU, Hoyer J Klinische Psychologie & Psychotherapie (2020) Springer-Lehrbuch, 2., \u00fcberarbeitete und erweiterte Auflage, Springer, Berlin, Heidelberg"},{"key":"2658_CR51","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 67:361\u2013370","journal-title":"Acta Psychiatrica Scandinavica"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02658-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:01:57Z","timestamp":1741024917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02658-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2658"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02658-y","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BW received travel grants and speaker honoraria from Desitin and Merz and research funding from Allergan and Merz Non-financial interests: BW is member of the scientific board of the Deutsche Dystonie Gesellschaft (German Dystonia Society, patient-association) RL has no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the relevant Institutional Ethics Committee of University Hospital of Bonn (protocol codes 156\/07 and 281\/13).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"BW is member of the scientific board of the Deutsche Dystonie Gesellschaft (German Dystonia Society, patient-association); RL none.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Non-financial interests"}}]}}